Drug Testing and Analysis
May 7, 2022
Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al.
14 citations
Abstract Lysergic acid diethylamide (LSD) is known to induce powerful psychoactive effects in humans, which cemented its status as an important tool for clinical research. A range of analogues and derivatives has been investigated over the years, including those classified as new psychoactive substances. This study presents the characterization of the novel lysergamide N , N...
European Journal of Futures Research
April 30, 2022
Claudia Schwarz-Plaschg
36 citations
Abstract After decades of criminalization, psychedelic substances such as psilocybin and LSD are experiencing their comeback in science and Western culture more broadly. While psychedelic plants and fungi have a long history of use in Indigenous cultures, the Western prohibitionist reality instantiated around 1970 has stigmatized psychedelics as medically useless and a threat to society. Yet...
Philosophy and the Mind Sciences
April 19, 2022
Chris Letheby
3 citations
In this précis I summarise the main ideas of my book Philosophy of Psychedelics. The book discusses philosophical issues arising from the therapeutic use of “classic” (serotonergic) psychedelic drugs such as psilocybin and LSD. The book is organised around what I call the Comforting Delusion Objection to psychedelic therapy: the concern that this novel and promising treatment relies essentially...
Molecules
April 13, 2022
Henry Lowe, Ngeh J. Toyang, Blair Steele et al.
53 citations
The word “psychedelic” (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic drugs such as N,N-DMT/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), MDMA...
Scientific Reports
April 7, 2022
Grant Jones, Jocelyn A. Ricard, Joshua Lipson et al.
56 citations
Abstract Opioid use disorder (OUD) is a major source of morbidity and mortality in the U.S. and there is a pressing need to identify additional treatments for the disorder. Classic psychedelics (psilocybin, peyote, mescaline, LSD) have been linked to the alleviation of various substance use disorders and may hold promise as potential treatments for OUD. The aim of this study was to assess...
International Journal for the Study of New Religions
March 23, 2022
Anna Lutkajtis
3 citations
Recently there has been a surge of renewed interest in the psychedelic compound psilocybin. In particular, psilocybin is being studied in clinical settings as a potential breakthrough treatment for depression. Alongside this growing therapeutic interest, there has been a rise in the religious use of psilocybin, as evidenced by the creation of a number of psilocybin mushroom churches in the...
Frontiers in Epidemiology
March 23, 2022
Alan K. Davis, Brooke J. Arterberry, Yitong Xin et al.
20 citations
Background The current study is one of the first to examine race, ethnic, and sex differences in the prevalence of and trends in hallucinogen use among lifetime users in the United States. Methods Data came from the 2015–2019 National Survey on Drug Use and Health and included respondent's reporting ever-using hallucinogens ( n = 41,060; female = 40.4%). Descriptive and multinomial logistic...
Frontiers in Pharmacology
March 22, 2022
Enzo Tagliazucchi
20 citations
Psychedelics are drugs capable of eliciting profound alterations in the subjective experience of the users, sometimes with long-lasting consequences. Because of this, psychedelic research tends to focus on human subjects, given their capacity to construct detailed narratives about the contents of their consciousness experiences. In spite of its relevance, the interaction between serotonergic...
Cambridge University Press eBooks
March 20, 2022
Timmen Cermak
Jackson was bored with his massage therapy practice and was looking for something more interesting to do. Cannabis legalization had reawakened his interest in the use of natural, psychoactive substances as healing and spiritual agents. A once-a-month user of cannabis, he was enthusiastic about Johns Hopkins University’s research on the potential mental health benefits of psilocybin, the...
Journal of Counseling & Development
March 19, 2022
Benjamin Hearn, Michael D. Brubaker, George B. Richardson
46 citations
Abstract The ‘‘psychedelic renaissance’’ is generating new evidence for psychedelics’ potential to treat numerous mental and substance use disorders. In particular, the United States Food and Drug Administration is poised to approve psychedelic drugs 3,4 methylenedioxymethamphetamine (MDMA) and psilocybin for the use in psychedelic‐assisted therapy (PAT). This renaissance has led to substantial...